Loading…
Inhibrx Biosciences, Inc. is projected to rise to $116.26 by 2027, a +25% move from its current price of $93.01. INBX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $89.64 | $93.05 | $96.59 | +0.04% |
| Jul 13 | $88.30 | $93.09 | $98.13 | +0.08% |
| Jul 14 | $87.30 | $93.13 | $99.34 | +0.12% |
| Jul 15 | $86.46 | $93.16 | $100.38 | +0.17% |
| Jul 16 | $85.74 | $93.20 | $101.31 | +0.21% |
| Jul 17 | $85.10 | $93.24 | $102.17 | +0.25% |
| Jul 18 | $84.51 | $93.28 | $102.96 | +0.29% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $84.51 | $93.28 | $102.96 | +0.29% |
| Week 2 | $81.36 | $93.55 | $107.57 | +0.58% |
| Week 3 | $79.08 | $93.82 | $111.32 | +0.87% |
| Week 4 | $77.24 | $94.10 | $114.64 | +1.17% |
| Week 5 | $75.68 | $94.37 | $117.68 | +1.46% |
| Week 6 | $74.31 | $94.64 | $120.54 | +1.76% |
| Week 7 | $73.10 | $94.92 | $123.25 | +2.05% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company that develops biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1 and targets death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma, and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumors, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
The company was incorporated in 2024 and is based in La Jolla, California.
INBX is the stock ticker for Inhibrx Biosciences, Inc., a healthcare-focused biopharmaceutical company. It trades at $93.01 and has a market capitalization of $1.36B, with a rank of 2317. The current price and capitalization place it among smaller-cap healthcare equities with a clinical-stage portfolio evident in INBRX-109 and INBRX-106.
The price outlook shown in the year-by-year forecast indicates upside potential over the long term, with yearly averages moving higher from 2026 onward.
A major floor 37.2% below — a decisive break under it would weaken the trend.
The nearest floor, 6.5% below — buyers have tended to step in here.
The nearest ceiling, 11.8% above — a clean break opens room to run.
A major ceiling 52.5% above — clearing it would confirm fresh momentum.
Key INBX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INBX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $98.37 | Sell | $97.42 | Sell |
| MA 10 | $96.94 | Sell | $96.99 | Sell |
| MA 20 | $95.29 | Sell | $96.73 | Sell |
| MA 50 | $104.27 | Sell | $97.07 | Sell |
| MA 100 | $91.05 | Buy | $91.99 | Buy |
| MA 200 | $79.85 | Buy | $78.60 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.83 | Neutral |
| Stoch RSI (14) | 7.75 | Buy |
| CCI (20) | -74.95 | Neutral |
| Williams %R (14) | -99.09 | Info |
| MACD (12,26,9) | 0.79 | Buy |
| ROC (12) | 0.11 | Buy |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 0.91 | Buy |
| TRIX (15) | -0.21 | Sell |
| Awesome (5,34) | 2.21 | Buy |
| Ultimate (7,14,28) | 47.01 | Neutral |
| Momentum (10) | -2.30 | Sell |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 99.71 | Sell |
| ADX (14) | 11.40 | Neutral |
| ATR (14) | 3.05 | Info |
Technical sentiment is bullish. The RSI(14) is 40, with the 50-day simple moving average at $104.27 and the 200-day simple moving average at $79.85. Immediate support is at $87.01 and resistance at $104.01.
The stock has traded over a 30-day range of $72.73 to $118.95, and annualized volatility stands at 70%. In the near term, price action could test the resistance near $104.01 or pull back toward the support near $87.01, depending on market dynamics and news flow.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $58.39 | $93.01 | $134.46 | 0% | Neutral | |
| $89.40 | $116.26 | $161.72 | +25% | Bullish | |
| $97.98 | $132.57 | $193.46 | +43% | Bullish | |
| $127.50 | $178.35 | $270.12 | +92% | Bullish | |
| $165.75 | $238.84 | $373.14 | +157% | Bullish | |
| $171.37 | $253.76 | $407.29 | +173% | Bullish | |
| $177.24 | $269.26 | $442.65 | +189% | Bullish | |
| $189.28 | $294.59 | $494.91 | +217% | Bullish | |
| $192.85 | $307.19 | $526.41 | +230% | Bullish | |
| $250.24 | $407.63 | $711.46 | +338% | Bullish | |
| $301.35 | $544.51 | $1,025.63 | +485% | Bullish | |
| $686.68 | $1,498.05 | $3,147.16 | +15.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $58.39 | $93.01 | $110.34 | +0.00% |
| August 2026 | $79.46 | $94.74 | $116.68 | +1.86% |
| September 2026 | $80.23 | $96.59 | $120.74 | +1.96% |
| October 2026 | $78.18 | $94.90 | $120.11 | -1.75% |
| November 2026 | $80.05 | $97.87 | $125.16 | +3.13% |
| December 2026 | $84.62 | $104.14 | $134.46 | +6.41% |
Click any year to see its month-by-month INBX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect INBX to range from $58.39 to $134.46 through 2026. The $93.01 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The INBX price prediction for 2027 points to an average of $116.26 (low $89.40, high $161.72) — a potential gain of +25% on today's $93.01. Buyers look set to stay in control over this stretch.
In 2028, INBX is projected to trade between $97.98 and $193.46, averaging $132.57 — a potential gain of +43% from today's $93.01. That is up +14% on the projected 2027 average. Momentum favours further upside here.
Inhibrx Biosciences, Inc.'s 2029 outlook centres on $178.35, within a $127.50 to $270.12 range. That is up +35% on the projected 2028 average. That marks a +92% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, INBX could reach as high as $373.14, with a base case around $238.84 and support toward $165.75 — roughly +157% from $93.01. Momentum favours further upside here.
Expect INBX to range from $171.37 to $407.29 through 2031. The $253.76 average target implies a +173% move from current prices. That is up +6% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The INBX price prediction for 2032 points to an average of $269.26 (low $177.24, high $442.65) — a potential gain of +189% on today's $93.01. Momentum favours further upside here.
In 2033, INBX is projected to trade between $189.28 and $494.91, averaging $294.59 — a potential gain of +217% from today's $93.01. That is up +9% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Inhibrx Biosciences, Inc.'s 2034 outlook centres on $307.19, within a $192.85 to $526.41 range. That is up +4% on the projected 2033 average. That marks a +230% change versus current levels. Momentum favours further upside here.
By 2035, INBX could reach as high as $711.46, with a base case around $407.63 and support toward $250.24 — roughly +338% from $93.01. Buyers look set to stay in control over this stretch.
Expect INBX to range from $301.35 to $1,025.63 through 2040. The $544.51 average target implies a +485% move from current prices. That is up +34% on the projected 2035 average. Momentum favours further upside here.
The INBX price prediction for 2050 points to an average of $1,498.05 (low $686.68, high $3,147.16) — a potential gain of +15.1x on today's $93.01. Buyers look set to stay in control over this stretch.
Investing $1,000 in INBX today (≈ 10.751532 INBX) could be worth
$16,106.28
+$15,106.28 (+1511%) by 2050 · US Dollar
Based on the average projected INBX price of $1,498.05 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INBXwould be worth at today's price.
$1,000 invested in INBX on Jul 10, 2025 (≈ 47.664443 INBX) would be worth
$4,433.27
+$3,433.27 (+343.3%) today · 4.43× · US Dollar
Based on a INBX entry price of $20.98 vs. today's $93.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $97.58 | $953.17 | -4.7% |
| 1 month ago | $89.47 | $1,039.57 | +4.0% |
| 3 months ago | $75.27 | $1,235.68 | +23.6% |
| 6 months ago | $75.94 | $1,224.78 | +22.5% |
| 1 year ago | $20.98 | $4,433.27 | +343.3% |
| All time (2.1y) ago | $12.51 | $7,436.79 | +643.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INBX forecast.
Our base-case forecast reaches $190.00 around 2030.
Implied market cap at $190.00: $2.79B
The multi-year forecast shows a strong bullish trajectory from 2027 onward, with the average price climbing from $116.26 in 2027 to $238.84 in 2030 and then to $1,498.05 by 2050. The forecast also shows substantial upside in max values, reaching $3,147.16 by 2050, with a long-run ROI of 1510.6%. Specific milestones include 2030 average of $238.84 (ROI 156.8%) and 2040 average of $544.51 (ROI 485.4%), followed by 2050 average of $1,498.05 (ROI 1510.6%).
The forecast consistently labels sentiment as BULLISH from 2027 onward, underscoring a long-horizon upside despite inherent uncertainty in such projections.
Tap a question to reveal the answer.
Current price: $93.01. Market cap: $1.36B.
2027 forecast: min $89.40, avg $116.26, max $161.72; ROI 25; sentiment BULLISH.
2040 forecast: min $301.35, avg $544.51, max $1,025.63; ROI 485.4; sentiment BULLISH.
2050 forecast: min $686.68, avg $1,498.05, max $3,147.16; ROI 1510.6; sentiment BULLISH.
2026 forecast: min $58.39, avg $93.01, max $134.46; ROI 0; sentiment NEUTRAL.
Inhibrx Biosciences, Inc. Community Discussion
0Share your Inhibrx Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.